Inotiv
Inotiv is a pharmaceutical development company that specializes in nonclinical and analytical drug discovery and development services for the pharmaceutical, chemical, and medical device sectors. The company operates through two primary segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment provides comprehensive support for the discovery and nonclinical development of small molecule drug candidates, biotherapeutics, and biomedical devices, catering to the needs of researchers and clinicians. Meanwhile, the RMS segment offers a diverse range of small and large research models, facilitating basic research and drug development processes. Inotiv's services encompass biopharmaceutical analytics, reproductive toxicology, medical device testing, drug metabolism and pharmacokinetics (DMPK), and consulting, positioning the company as a key player in the drug development landscape.
Top Stages
4 past transactions
Protypia
Acquisition in 2022
Protypia is an emerging bioanalytical company specializing in targeted proteomics, focusing on the precise quantification of proteins and peptides in various biological samples. The company offers a high-quality platform for mass spectrometry that allows for the analysis of drug target systems in cells, tissue models, and human tissues. By integrating protein-level pharmacology and pathology, Protypia supports multiple therapeutic areas and modalities throughout the drug development process, from initial discovery to clinical development. This enables clients to effectively analyze drug targets and identify essential protein features, facilitating advancements in therapeutic research.
Histion
Acquisition in 2022
Histion is a provider of preclinical services focused on histopathology and medical device evaluations. The company offers scientific and technical expertise to the Medical Device, Pharmaceutical, and Biotechnology industries. Histion's laboratory specializes in a variety of product types, including novel biomaterials, drugs, biologics, and delivery devices such as cutaneous, percutaneous, implantable, injectable, and ingestible options for clinical applications. This comprehensive approach enables clients to meet their product development needs effectively.
Envigo
Acquisition in 2021
Envigo provides essential products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Their company is founded on the principle that research partnerships depend on unmatched expertise, unwavering dedication to customer service and shared goals, Envigo is committed to helping customers realize the full potential of their products and research which contribute to enhancing the lives of people and animals as well as protecting the environment.
Plato Biopharma
Acquisition in 2021
Plato BioPharma is a preclinical drug discovery contract research organization (CRO) focused on in vivo physiological and pharmacological studies. The company specializes in the therapeutic areas of cardiovascular, renal, pulmonary, diabetes, and hepatic diseases. By conducting pathophysiological and pharmacological research, Plato BioPharma generates decision-enabling data through the physiological evaluation of disease models and the assessment of both acute and chronic pharmacologic responses. This research aims to support the development of treatments that can address life-threatening conditions, ultimately helping patients lead healthier lives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.